Repurposing FDA-approved drugs as potential PARP inhibitors

被引：0
|
作者：
Eznarriaga, Maria [1 ]
Rahman, Taufiq [1 ]
机构：
[1] Univ Cambridge, Cambridge, England
来源：
BRITISH JOURNAL OF PHARMACOLOGY | 2020年 / 177卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P070
引用
收藏
页码：2516 / 2516
页数：1
相关论文
共 50 条
  • [21] Structure-based repurposing of FDA-approved drugs as inhibitors of NEDD8-activating enzyme
    Zhong, Hai-Jing
    Liu, Li-Juan
    Chan, Daniel Shiu-Hin
    Wang, Hui-Min
    Chan, Philip Wai Hong
    Ma, Dik-Lung
    Leung, Chung-Hang
    BIOCHIMIE, 2014, 102 : 211 - 215
  • [22] Drug repurposing for Alzheimer's disease: in silico and in vitro investigation of FDA-approved drugs as acetylcholinesterase inhibitors
    Kumar, Navneet
    Gahlawat, Anuj
    Kumar, Rajaram Naresh
    Singh, Yash Pal
    Modi, Gyan
    Garg, Prabha
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (07): : 2878 - 2892
  • [23] Repurposing of FDA-Approved drugs to predict new inhibitors against key regulatory genes in Mycobacterium Tuberculosis
    Yang, Xinjun
    Alam, Aftab
    Iqbal, Naiyar
    Raza, Khalid
    BIOCELL, 2021, 45 (06) : 1569 - 1583
  • [24] Repurposing FDA-Approved Compounds for the Discovery of Glutaminyl Cyclase Inhibitors as Drugs Against Alzheimer's Disease
    Xu, Chenshu
    Zou, Haoman
    Yu, Xi
    Xie, Yazhou
    Cai, Jiaxin
    Shang, Qi
    Ouyang, Na
    Wang, Yinan
    Xu, Pan
    He, Zhendan
    Wu, Haiqiang
    CHEMISTRYOPEN, 2021, 10 (09): : 877 - 881
  • [25] Repurposing FDA-approved drugs against the toxicity of platinum-based anticancer drugs
    Famurewa, Ademola C.
    Mukherjee, Anirban Goutam
    Wanjari, Uddesh Ramesh
    Sukumar, Aarthi
    Murali, Reshma
    Renu, Kaviyarasi
    Vellingiri, Balachandar
    Dey, Abhijit
    Gopalakrishnan, Abilash Valsala
    LIFE SCIENCES, 2022, 305
  • [26] In Silico and In Vitro Potential of FDA-Approved Drugs for Antimalarial Drug Repurposing against Plasmodium Serine Hydroxymethyltransferases
    Mee-udorn, Pitchayathida
    Phiwkaow, Kochakorn
    Tinikul, Ruchanok
    Sanachai, Kamonpan
    Maenpuen, Somchart
    Rungrotmongkol, Thanyada
    ACS OMEGA, 2023, 8 (39): : 35580 - 35591
  • [27] Disruption of Irisin Dimerization by FDA-Approved Drugs: A Computational Repurposing Approach for the Potential Treatment of Lipodystrophy Syndromes
    Flori, Lorenzo
    Brogi, Simone
    Sirous, Hajar
    Calderone, Vincenzo
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (08)
  • [28] Repurposing of FDA-approved drugs to target MurB and MurE enzymes in Mycobacterium tuberculosis
    Rani, Jyoti
    Silla, Yumnam
    Borah, Kasmika
    Ramachandran, Srinivasan
    Bajpai, Urmi
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2020, 38 (09): : 2521 - 2532
  • [29] Repurposing of FDA-approved lead drugs as potentiators of uterine contractility in postpartum hemorrhage
    Iwueke, Chisom C.
    Hansen, Christopher J.
    Siricilla, Shajila
    Herington, Jennifer L.
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2021, 224 (02) : S325 - S325
  • [30] Repurposing FDA-approved drugs to target G-quadruplexes in breast cancer
    Moraca, Federica
    Arciuolo, Valentina
    Marzano, Simona
    Napolitano, Fabiana
    Castellano, Giuliano
    D'Aria, Federica
    Di Porzio, Anna
    Landolfi, Laura
    Catalanotti, Bruno
    Randazzo, Antonio
    Pagano, Bruno
    Malfitano, Anna Maria
    Amato, Jussara
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 285
12345